The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday.

The breast cancer drug was shown this year to help a wider patient group in a study, in a major win for CEO Vas Narasimhan.

The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta.

Last month, the Basel-based drugmaker spun off and listed generic drugs business Sandoz and raised its 2023 earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for the MS drug.

The Swiss company, which is updating investors on its research and development on Tuesday, reiterated it was aiming for a core operating income margin of at least 40% by 2027, up from 35% last year.

It also reiterated a focus of its drug development on the four therapy areas cardio-renal care, immunology, neuroscience, oncology and haematology, according to a statement on Tuesday.

(Reporting by Ludwig Burger; Editing by Miranda Murray and Miral Fahmy)

By Ludwig Burger